Effects of the antimycobacterial compound 2-phenoxy-1-phenylethanone on rat hepatocytes and formation of metabolites


Autoria(s): Rodrigues Coutinho, Ana Paula; Beraldo de Moraes, Luiz Alberto; Soares Barata, Lauro Euclides; de Souza, Ana Olivia
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

23/10/2013

23/10/2013

2012

Resumo

Context: Neolignans are usually dimers formed by oxidative coupling of allyl and propenyl phenols, and the neolignan analogue, 2-phenoxy-1-phenylethanone (LS-2) is a promising antimycobacterial compound showing very weak cytotoxicity in mammalian cells and lack of acute toxicity in murine models. Objectives: To investigate the mechanism of action of LS-2 in rat hepatocytes by evaluating the activity levels of enzymes related to oxidation status and drug-metabolizing activity. Materials and methods: Hepatocytes were treated with LS-2 from 0.05 up to 1 mM, for 24 and 48 h, and reduced glutathione (GSH), lipid peroxidation and cytochrome P450 enzyme (CYP450) activity were assayed. A homologous series of phenoxazone ethers were used as substrates to measure the enzymatic profile. The biotransformation of LS-2 was studied in hepatocytes by gas chromatography-mass spectrometry (GC-MS) for detection and analysis of possible metabolites. Results: Hepatocytes treated with LS-2 up to 1 mM for 24 or 48 h did not induce the formation of GSH and lipid peroxidation. O-Dealkylation activities of the isoenzymes CYP4501A1, CYP4501A2, CYP4502B1 and CYP4502B2 were also not detected in the hepatocytes treated with LS-2 for 24 or 48 h. Discussion and conclusion: The results indicate that LS-2 or its two detected metabolites, 2-phenoxy-1-phenylethanol and 2,4-(2-hydroxy-2-phenylethoxy) phenol, are not cytotoxic to rat hepatocytes. These compounds maintain a balance between the production of pro-oxidant agents and their respective antioxidant systems. The data show that enzymes related to oxidation status and drug-metabolizing activities are not involved in the mechanism of action of LS-2.

Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/FAPESP)

Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/FAPESP)

Identificador

PHARMACEUTICAL BIOLOGY, LONDON, v. 50, n. 10, supl. 4, Part 1, pp. 1317-1325, OCT, 2012

1388-0209

http://www.producao.usp.br/handle/BDPI/35610

10.3109/13880209.2012.674949

http://dx.doi.org/10.3109/13880209.2012.674949

Idioma(s)

eng

Publicador

INFORMA HEALTHCARE

LONDON

Relação

PHARMACEUTICAL BIOLOGY

Direitos

restrictedAccess

Copyright INFORMA HEALTHCARE

Palavras-Chave #BIOTRANSFORMATION #CYTOTOXICITY #METABOLITES #REDUCED GLUTATHIONE (GSH) #LIPID PEROXIDATION #CYTOCHROME P450 ACTIVITY (CYP450) #ENZYME-ACTIVITY #CYTOTOXICITY #TOXICITY #ANTIOXIDANTS #PEROXIDATION #VARIABILITY #INVESTIGATE #NEOLIGNANS #ANALOGS #ASSAY #PLANT SCIENCES #MEDICAL LABORATORY TECHNOLOGY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion